RS BioTherapeutics

About:

RS BioTherapeutics is a research, development, and commercialization company focused on pulminary diseases.

Website: https://rsbiotherapeutics.com

Description:

Founded in 2021, the mission of RS BioTherapeutics is to develop life-changing medicines for the millions of people suffering from deadly lung diseases characterized by pulmonary inflammation. RS BioTherapeutics is developing a first-in-class, steroid-free, multi-targeted immune modulator (RSBT-001) with Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis (IPF), and Pulmonary Arterial Hypertension (PAH) as potential first indications. RS BioTherapeutics owns the exclusive, global license for RSBT-001 and is projecting filing an Investigational New Drug Application for RSBT-001 and initiating human trials in late 2026.